introduction fungal microorganism etiological factor severe often deadly infectious disease especially immunocompromised patient number patient growing rapidly disease resulting immunodeficiency like aid also consequence frequent use therapy affect human immune defense system e.g.anticancer therapy cytostatics steroid therapy use immunosuppressive agent transplant patient systemic mycoses caused patient mainly yeast-like microorganism candida genus especially candida albicans candida glabrata filamentous fungi aspergillus genus hand many fungal microorganism known one frequent reason nosocomial infection albicans considered fourth popular etiological agent nosocomial infection worldwide moreover chemotherapeutics used clinical treatment become factor stimulating selection resistant cell newly described pathogen candida auris emerging multidrug-resistant organism pose global threat additionally invasive fungal infection complicate clinical course covid-19 associated significant increase mortality especially critically ill patient admitted intensive care unit thus current massive increase drug-resistant microbial infection well significant role fungal infection death toll covid-19 discovering new antifungal compound extremely important several approach novel drug discovery first researcher looking new drug targeting old pathway e.g. ergosterol synthesis cell membrane others trying find new solution biosynthesis fungal protein dna essential molecule extremely important long new target concerned group looking new drug targeting fungal topoisomerases significant work done structure function topoisomerase fungi result indicated activity crucial specific strain moreover inhibition yeast topoisomerase resulted antifungal activity even managed overcome fluconazole-resistance natural xanthone derivative promising group antifungal compound present nature metabolite various plant lichen fungal bacterial specie interesting structural scaffold biological efficacy compound lead many scientist synthesize xanthone derivative development new prospective drug candidate anticancer antimicrobial antimalarial anti-hiv antioxidant anti-inflammatory antimalarial agent several article published highlighting antifungal activity synthetic xanthone analogue although examined thoroughly order define mechanism action according previous report 1,2-dihydroxyxanthone active compound fungal strain tested showing effect sterol biosynthesis reducing amount ergosterol detected emerging previous study performed xanthone analogue potential antimicrobial decided analyze antifungal activity four new group compound xanthone derivative anticancer activity reported effective human topoisomerase inhibitor also analyzed inhibitory effect selected derivative yeast topoisomerase activity ytopo result discussion synthesis xanthone derivative structure xanthone derivative synthesized study divided four group fig compound prepared according previously published procedure 35–38 41–45 newly synthesized analogue table group i–iv differ nitro amino substitution presence pyrazole benzene fused ring xanthone core fig figure overall structure derivative analysed study —aminosubstitution —no full size image table list xanthone group benzoxanthone group iii analoques full size table list xanthone benzoxanthone analogue analyzed study presented table synthesis new compound used analogous synthetic procedure slight alteration fig briefly reaction ethyl salicylate ethyl 3-hydroxy-2-napthoate 2,4-dichloronitrobenzene afforded mixture isomeric diarylethers respectively trituration mixture methanol resulted pure obtained 1/1 mixture could purified synthesis ortho-substituted amine mixture saponified mild condition without purification resulting mixture acid ring closed upon treatment polyphosphoric acid ppa afford nitro compound respectively inseparable mixture reaction mixture suitable amine resulted aminoderivatives respectively aminoderivative isolated pure form column chromatography identified mean spectral data using direct long-range experiment hmbc hmqc order prepare corresponding p-substituted nitro derivative 35–38 41–45 ethyl ester saponified ring closed upon treatment ppa afford nitrosubstituted benzoxanthone pure form consequently amino derivative 35–38 prepared upon nucleophilic substitution chloro group appropriately substituted amine synthesis amine compound converted mesylates treated appropriately substituted amine result amino derivative respectively figure reaction condition dmf dry naoh etoh ppa suitable amine pyridine reflux full size image figure reaction condition dmf dry naoh etoh ppa suitable amine pyridine reflux suitable amine pyridine reflux mscl thf suitable amine etoh reflux full size image susceptibility testing novel compound fungal strain derivative tested vitro antifungal activity five reference fungal strain american type culture collection atcc table active compound tested six albicans clinical isolates sensitive gu4 resistant gu5 fluconazole table minimal inhibitory concentration mics studied compound determined microplate serial dilution method table antifungal activity reference strain mic minimal inhibitory concentration—a concentration inhibits fungal cell growth full size table table antifungal activity selected derivative clinical strain comparison albicans atcc full size table reported table active reference strain group iii derivative group compound 13–15 although depends strain latter structure activity relationship analysis revealed presence naphthalene ring well nitro group position fig crucial antifungal activity thus decided synthesize additional derivative compound 35–38 41–45 approach allowed obtain derivative even better antifungal activity reference strain starting derivative active compound mic also determined six albicans clinical isolates sensitive gu4 resistant gu5 fluconazole flu-resistant clinical albicans gu5 strain sensitive selected derivative table derivative level flu-sensitive counterpart gu4 mics higher flu-resistant cell still measurable active reference strain compound well also exhibited highest antifungal activity clinical strain including flu-resistant interestingly antifungal activity compound reference strain glabrata well parapsilosis significant table found active clinical albicans strain sensitive resistant strain gu4 fluconazole-sensitive isolates obtained early infection episode gu5 corresponding fluconazole-resistant isolates obtained later episode patient treated fluconazole case gu5 lack susceptibility fluconazole consequence overexpression cdr1/2 gene encoding abc transporter whereas resistance strain caused overexpression mdr1 gene encoding membrane transport protein major facilitator superfamily result indicate active compound substrate pump efflux drug resistant cell antifungal activity doe depend type overexpressed pump molecular mechanism antifungal activity killing activity selected derivative establish possible mode action xanthone benzoxanthone analogue analyzed killing activity determined minimal fungicidal concentration mfcs selected derivative table table fungicidal activity selected compound amphotericin mfc—minimal fungicidal concentration—a concentration inhibits fungal cell growth full size table result indicate mode action active compound fungicidal higher fungicidal activity determined derivative group iii group use fungicidal therapy invasive candidiasis candidemia associated higher probability early therapeutic success decreased probability persistent recurrent infection resistance development also expected addition frequent use available fungistatic drug like fluconazole promotes drug resistance light demonstrated killing activity examined derivative undoubted advantage inhibition relaxation activity yeast topoisomerase vitro xanthone derivative act anticancer agent several mechanism action important activation caspase protein inhibition protein kinase topoisomerases due known activity xanthone derivative human topoisomerase inhibitor decided evaluate influence six active compound fungal equivalent enzyme effect selected compound yeast topoisomerase ii-mediated relaxation activity suggests molecular target table fig table concentration selected compound totally inhibited yeast topoisomerase ii-mediated relaxation activity full size table figure inhibition catalytic activity purified yeast dna topoisomerase compound measured relaxation supercoiled pbr322 plasmid dna topo relaxed purified yeast topoisomerase absence topo presence analyzed compound 1–150 concentration 1–50 higher concentration tested due low solubility compound resulting topological form dna separated gel electrophoreses supercoiled dna relaxed dna dna topoisomers data shown typical three independent experiment one set representative picture shown original gel presented supplementary fig full size image reported table effective inhibitor towards fungal topoisomerase compound surprisingly inhibition observed tested concentration range compound closely related derivative thus molecular mode action may vary compound need depth analysis selectivity relation mammalian cell selected compound screened vitro antiproliferative activity towards human embryonic kidney cell line hek-293 human liver cancer cell line hepg2 using colorimetric mtt assay result compared cytotoxic activity determined previously human colorectal adenocarcinoma cell line ht29 presented table table determination cytotoxic effect using mtt assay towards hek293 hepg2 cell line full size table indicated etoposide doxorubicin chemotherapy drug used treat different type cancer result obtained newly synthezised compound within acceptable cytotoxicity level estimate selectivity relation mammalian cell mycostatic selectivity index msi albicans atcc calculated ratio mic value converting mic value micromolar concentration result presented table table mycostatic selectivity index value determined albicans atcc relation mammalian cell line hek293 hepg2 full size table positive mycostatic selectivity index value msi obtained selected derivative ranging 0.105 0.655 result indicate possibility using xanthone derivative efficient antifungal agent however necessary improve selectivity compound interesting higher level msi using hepg2 cell obtained hepg2 cell line derived human liver cancer commonly used study drug metabolism toxicity material method chemical synthesis general experimental procedure commercially available reagent solvent purchased alfa aesar used without purification melting point determined büchi apparatus uncorrected nmr spectrum recorded mhz bruker spectrometer respectively avance™ drx iii instrument bruker biospin gmbh–rheinstetten germany nmr mhz nmr mhz recorded complete proton decoupling spectrum obtained sample dissolved cdcl dmso‐ residual solvent signal used internal reference 7.26 ppm chcl 2.50 ppm regarding nmr experiment 77.2 ppm cdcl 39.4 ppm concerning nmr experiment chemical shift given ppm nearest 0.01 0.1 ppm coupling constant given hertz signal reported follows singlet doublet triplet multiplet broad assignment nmr signal unambiguously achieved help d/h exchange technique cosy noesy hmqc hmbc experiment compound 1–8 10–16 synthesized according literature nmr nmr compared reported literature flash chromatography performed merck silica gel 40–63 indicated solvent system using gradient increasing polarity case merck kgaa—darmstadt germany reaction monitored analytical thin-layer chromatography merck pre-coated silica gel f254 tlc plate 0.25-mm layer thickness compound visualized tlc plate radiation solvent absorption fluorescence experiment spectroscopic grade mass spectrum recorded uplc triple tof–ms uplc acquity water usa sciex triple tof–ms usa general procedure synthesis amino substituted xanthones solution ethyl salicylate 1.66 mmol 2,4-dichloronitrobenzene 1.91 9.95 mmol 1.38 mmol mmol dry dmf heated argon atmosphere completion reaction mixture filtered hot washed etoac filtrate vacuum evaporated oily residue diluted washed water dried anh evaporated dryness obtained oily residue triturated hot ethanol stirring cooling filtrated afford 1.0 1.2 oily mixture ester used next step without purification suspension mixture ethanol cold naoh solution added resulting mixture stirred room temperature min completion reaction mixture poured ice-water acidified hcl solution resulting mixture acid filtered dried dissolved hot polyphosphoric acid resulting mixture stirred upon cooling poured ice precipitate filtered dried afford xanthones used next step without purification thus suitable amine dry pyridine refluxed 1/2 completion reaction pyridine vacuum evaporated oily residue diluted etoac washed water dried anh evaporated dryness flash chromatography silica gel using mixture 93/7 elouent afforded title compound isomer respectively data diethylamino ethyl amino -2-nitro-9 -xanthen-9-one yield m.p 123–124 etoac– -hexane nmr mhz cdcl 10.89 exchang. 8.26 7.9 1.7 8.09 9.2 7.69 7.9 1.7 7.46–7.36 6.57 9.3 3.03 5.7 2.72 5.7 2.65 7.1 1.08 7.1 nmr mhz cdcl 179.0 161.0 155.1 148.2 135.2 134.3 130.6 126.8 125.2 122.2 117.8 109.8 104.0 52.1 47.2 45.4 12.0 esi qqtof m/z calcd 356.1605 found 356.1614 data 2-nitro-1- pyrrolidin-1-yl ethyl amino -xanthen-9-one yield m.p 173–175 etoac–n-hexane nmr mhz cdcl 10.88 exchang. 4.7 8.21 7.9 1.7 8.06 9.3 7.68 8.6 1.7 7.45–7.32 6.56 9.3 3.13 6.3 2.84 6.3 2.66 1.85 nmr mhz cdcl 178.9 160.5 154.6 147.6 134.9 133.9 130.1 126.3 124.8 121.6 117.4 109.2 103.7 54.9 54.0 46.0 23.7 esi qqtof m/z calcd 354.1448 found 354.1440 2-nitro-1- pyrrolidin-1-yl ethyl amino -12 -benzo xanthen-12-one compound prepared analogous procedure described starting ethyl 3-hydroxy-2-napthoate 2,4-dichloronitrobenzene flash chromatography silica gel using mixture 94/6 elouent afforded title compound para nitro substitutent compound yield m.p etoac nmr mhz cdcl 10.99 exchang. 6.0 8.85 8.17 9.4 8.08 8.3 7.93 8.3 7.86 7.66 8.3 7.55 8.3 6.73 9.4 3.31 6.5 3,03 6.5 2.88 1.96 nmr mhz cdcl 180.0 161.2 150.6 148.0 136.8 134.5 130.3 130.2 129.8 129.6 128.3 127.2 126.2 120.6 113.4 108.6 105.5 54.0 43.3 23.5 esi qqtof m/z calcd 401.1605 found 401.1616 general procedure synthesis amino substituted benzo xanthones 35–38 solution pure benzo xanthone obtained synthesis suitable amine equiv dry pyridine refluxed completion reaction pyridine vacuum evaporated oily residue diluted etoac washed water dried anh evaporated dryness flash chromatography silica gel using mixture 100/1 elouent provided title compound data 2-hydroxyethoxy ethyl amino -4-nitro-12 -benzo xanthen-12-one yield oil nmr mhz cdcl 10.95 5.0 8.77 8.32 9.5 8.01 8.3 7.99 7.92 8.3 7.62 8.2 7.51 8.1 6.42 9.5 3.88 3.76–3.73 3.59 5.2 nmr mhz cdcl 180.1 155.9 154.0 150.7 136.9 134.1 130.4 129.8 129.5 127.8 127.5 126.3 125.5 120.9 114.3 104.8 103.4 72.9 68.6 62.1 42.8 esi qqtof m/z calcd 395.1238 found 395.1248 data 3-hydroxypropyl amino -4-nitro-12 -benzo xanthen-12-one yield m.p etoac nmr mhz cdcl 10.78 8.77 8.33 9.6 8.02 9.9 7.93 8.4 7.63 8.2 7.52 8.2 6.50 9.7 3.91 5.8 3.57 6.2 2.07 nmr mhz cdcl 180.0 156.1 154.0 150.7 136.8 134.0 130.3 129.8 129.5 127.6 127.5 126.3 125.3 120.9 114.3 104.6 103.4 60.3 40.3 31.5 esi qqtof m/z calcd 387.0951 found 387.0962 data 2-hydroxyethyl amino -4-nitro-12 -benzo xanthen-12-one yield m.p etoh-h nmr mhz cdcl meod 8.75 8.30 8.4 8.01 8.4 7.97 7.91 8.4 7.61 8.4 7.50 8.3 6.53 9.7 3.89 5.6 3.54 5.6 nmr mhz cdcl meod 180.4 156.7 154.5 151.0 137.3 134.4 130.8 130.1 129.9 128.0 127.9 126.7 125.5 121.3 114.6 105.0 104.2 60.4 45.7 esi qqtof m/z calcd m—h 349.0830 found 349.0825 data 3-methoxypropyl amino -4-nitro-12 -benzo xanthen-12-one yield m.p 174–176 etoac nmr mhz cdcl 10.76 8.78 8.32 9.7 8.03 8.4 8.00 7.93 8.4 7.63 8.3 7.52 8.1 6.48 9.7 3.57 5.7 3.55–3.49 3.41 2.05 nmr mhz cdcl 179.9 156.1 154.0 150.7 136.8 134.0 130.3 129.8 129.4 127.6 127.5 126.2 125.3 121.0 114.2 104.6 103.4 69.9 59.0 40.6 29.2 esi qqtof m/z calcd 401.1108 found 401.1115 general procedure synthesis amino substituted benzo xanthones 41–43 44–45 methanesulfonyl chloride 1.05 mmol added dropwise suspension mmol mmol mmol dry resulting mixture stirred room temperature completion reaction mixture washed hcl water organic layer dried vacuum evaporated without purification obtained crude mesylate respectivelly dissolved absolute ethanol solution suitable amine equiv added resulting solution stirred reflux solvent vacuum evaporated oily residue purified flash chromatography silica gel using mixture 9/1 elouent provide title compound data 3-morpholinopropyl amino -4-nitro-12 -benzo xanthen-12-one yield m.p 179–180 etoac– -hexane nmr mhz cdcl 10.73 exchang. 5.5 8.73 8.30 9.6 8.00 8.4 7.97 7.91 8.4 7.62 8.2 7.50 8.2 6.47 9.7 3.77 3.47 6.4 2.59–2.45 1.96 6.4 nmr mhz cdcl 179.7 155.9 153.8 150.5 136.6 133.8 130.2 129.6 129.3 127.4 126.1 125.1 120.8 114.1 104.4 103.3 67.0 56.0 53.8 41.3 25.7 esi qqtof m/z calcd 434.1710 found 434.1717 data 4-methylpiperazin-1-yl propyl amino -4-nitro-12 -benzo xanthen-12-one yield oil nmr mhz cdcl 10.74 exchang. 5.4 8.73 8.30 9.6 8.06–8.00 9.6 7.96 7.94–7.89 9.6 7.63 8.2 7.51 8.2 6.46 9.6 3.47 6.3 2.81 2.67 2.61 6.3 2.54 1.97 6.3 nmr mhz cdcl 179.5 155.6 153.6 150.3 136.5 133.6 130.0 129.5 129.2 127.2 127.1 126.0 125.0 120.5 114.0 104.2 103.1 55.3 54.1 51.5 44.7 41.4 25.5 esi qqtof m/z calcd 447.2027 found 447.2024 data 4-nitro-1- pyrrolidin-1-yl propyl amino -12 -benzo xanthen-12-one yield m.p 175–176 etoac– -hexane nmr mhz cdcl 10.73 exchang. 5.3 8.77 8.32 9.6 8.02 8.3 7.99 7.93 8.4 7.63 8.2 7.52 8.2 6.50 9.6 3.53 6.9 2.80 6.9 2.76 2.10 7.0 1.91 nmr mhz cdcl 179.8 155.8 153.7 150.5 136.7 133.8 130.2 129.6 129.3 127.4 127.3 126.0 125.2 120.8 114.1 104.4 103.3 54.0 53.4 41.3 27.4 23.5 esi qqtof m/z calcd 418.1761 found 418.1764 data 2-morpholinoethyl amino -4-nitro-12 -benzo xanthen-12-one yield m.p dec etoac— -hexane nmr mhz cdcl 10.87 exchang. 8.84 8.35 9.6 8.06 8.4 8.02 7.94 8.4 7.68–7.61 7.58–7.48 6.45 9.6 3.84 3.49 2.80 2.61 nmr mhz cdcl 179.8 155.7 154.0 150.7 136.8 134.0 130.4 129.8 129.4 127.7 127.5 126.2 125.5 121.1 114.3 104.8 103.6 67.2 56.4 53.6 40.2 esi qqtof m/z calcd 420.1554 found 420.1560 data 4-methylpiperazin-1-yl ethyl amino -4-nitro-12 -benzo xanthen-12-one yield m.p dec etoac– -hexane nmr mhz cdcl 10.83 exchang. 4.8 8.81 8.34 9.5 8.05 8.3 8.01 7.94 8.4 7.64 8.2 7.53 8.2 6.43 9.6 3.48 5.8 3.02–2.74 10h 2.57 nmr mhz cdcl 180.0 155.9 154.2 151.0 137.1 134.2 130.6 130.0 129.7 127.8 127.8 126.5 125.8 121.3 114.5 105.1 103.8 55.7 54.9 51.6 45.3 40.6 esi qqtof m/z calcd 433.1870 found 433.1870 microorganism strain growth condition following reference clinical fungal strain used albicans atcc glabrata atcc krusei atcc parapsilosis atcc cerevisiae atcc albicans albicans albicans gu4 albicans gu5 albicans albicans fungal strain used investigation routinely grown ypg liquid medium yeast extract peptone glucose shaking incubator growth solid medium 1.5 agar added ypg medium antifungal activity assay antifungal vitro activity determined modified m27-a3 specified clsi minimal inhibitory concentration mics determination described previously mic defined lowest drug concentration least decrease turbidity comparison drug-free control observed antifungal activity determined rpmi-1640 medium buffered 7.0 final concentration compound solvent dmso exceed 2.5 volume final suspension well influence growth microorganism minimum fungicidal concentration mfcs determined described previously spot assay mfc determined lowest concentration test compound recovery microorganism observed yeast topoisomerase relaxation assay inhibition inhibition yeast topoisomerase analysed according relaxation assay kit inspiralis inspiralis limited norwich described previously relaxation inhibition effectivity analyzed compound determined densitometry quantification transition supercoiled relaxed form expressed relation control gel photographed gel doc gel documentation system bio-rad hercules usa image processing performed gimp 2.10.18 antiproliferative activity determination human embryonic kidney cell line hek-293 human liver cancer cell line hepg2 purchased atcc manassas virginia usa hek-293 cultured dulbecco modified eagle medium hepg2 minimum essential medium eagle cell line culture medium supplemented fetal bovine serum -glutamine antibiotic penicillin 62.6 streptomycin cell cultured humidified atmosphere air routinely tested mycoplasma contamination antiproliferative activity compound determined previously described mtt method percentage cell viability calculated value determined using graphpad prism software version 8.3.1 conclusion xanthone benzoxanthone analogue synthesized evaluated antifungal activity benzoxanthones proved best antifungal agent positive mycostatic selectivity index value relation hek293 hepg2 cell line fused benzene ring thus crucial activity evaluation biological property suggests mode action effective derivative fungicidal demonstrated killing activity associated higher probability early therapeutic success decreased probability resistance development moreover clinical strain albicans resistant fluconazole due flu-induced overexpression cdr1p/cdr2p drug efflux pump well mdr1p membrane transport protein major facilitator superfamily remained sensitive novel compound finding suggests active clinical resistant strain compound good substrate abc well efflux pump since xanthone derivative human topoisomerase inhibitor antifungal activity analyzed compound may related inhibitory effect fungal equivalent enzyme result indicate strong relationship antifungal activity inhibitory effectiveness yeast topoisomerase summing able show proof concept xanthone modification may result discovery new group selective antifungal drug affecting fungal topoisomerase moreover result indicate possibility using derivative resistant fungal cell validation xanthones applicability antifungal designing synthesizing evaluating activity new inhibitor highly valuable future investigation focused improving selectivity